Overview

Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer

Status:
Completed

Trial end date:
2016-07-01

Target enrollment:

Participant gender:

Summary

The investigators propose a randomized phase II study evaluating the pCR and toxicity profiles of combination eribulin/cyclophosphamide (ErC) and docetaxel /cyclophosphamide (TC) as neoadjuvant therapy for locally advanced HER2-negative breast cancer.

Phase:

Phase 2

Details

Lead Sponsor:

SCRI Development Innovations, LLC

Collaborator:

Eisai Inc.

Treatments:

Cyclophosphamide
Docetaxel